Generated November 2, 2026 at 8:34 PM ET
· Covers November 2 trading day
· 6 of 305 ready 8-Ks selected
· AI-assisted overview
Six filings were selected, and three are completed merger or take-private closings: LXP Industrial Trust's $5.2 billion acquisition by Brookfield and CPP Investments at $61.20 per share, CBIZ's approximately $5 billion acquisition by Grant Thornton Advisors at $55.00 per share, and Strategic Storage Trust VI's $500 million all-stock merger with SSGT III. The LXP and CBIZ deals both closed with the targets delisted from the NYSE, and the CBIZ filing also disclosed a new CEO and the resignation of all directors and officers. Two cards cover positive regulatory actions: Inovio Pharmaceuticals received FDA accelerated approval for VOCERYQ in recurrent respiratory papillomatosis, and uniQure said the FDA accepted its Huntington's disease gene therapy BLA with Priority Review and a May 1, 2027 PDUFA date, with an advisory committee tentatively planned. One card covers a Nasdaq staff delisting determination after the bid price stayed at or below $0.10, with trading suspended at the open on Nov. 3. The set is somewhat repetitive, since three of the six cards are deal completions, and the highest materiality is concentrated in those M&A filings.
TBH
Brag House Holdings, Inc.
regulatory
negative
materiality 0.85
November 2, 2026, 4:15 PM ET
House of Doge faces Nasdaq delisting as bid price stays at $0.10 or below for 10 days
- Received Nasdaq Staff Delisting Determination on Oct 27, 2026; stock traded at $0.10 or less from Oct 13 through Oct 26, 2026.
- Trading suspended at open Nov 3, 2026; Form 25-NSE to remove HODO from Nasdaq Capital Market listing and registration.
- Initial Sept 9, 2026 deficiency letter gave until March 8, 2027 to regain the $1.00 minimum bid price; company has not regained compliance.
M&A
positive
materiality 1.00
November 2, 2026, 4:37 PM ET
Brookfield, CPP Investments close $5.2B LXP acquisition at $61.20/share; LXP delisted from NYSE
- LXP shareholders received $61.20 per common share in cash; transaction valued LXP at ~$5.2B including net debt and preferred equity.
- Each 6.50% Series C preferred share converted into a Series C Preferred Unit, then redeemed at $50.00 plus $1.1014 accrued dividends.
- LXP portfolio: 107 industrial properties, ~52M sq ft in Sunbelt and Midwest; to be folded into Brookfield's 255M+ sq ft global logistics platform.
M&A
positive
materiality 1.00
November 2, 2026, 9:21 AM ET
Grant Thornton Advisors completes $5 billion acquisition of CBIZ; CBZ delisted from NYSE
- CBIZ shareholders received $55.00 per share in cash; total funds used were approximately $5,235,000,000 from equity and debt financing.
- CBIZ became a wholly owned subsidiary of Viking ParentCo, an affiliate of Grant Thornton Advisors; CBZ ceased NYSE trading on November 2, 2026.
- Jim Peko was appointed CEO of the surviving corporation; all CBIZ directors and officers resigned at the effective time.
SGST
Strategic Storage Trust VI, Inc.
M&A
positive
materiality 0.92
November 2, 2026, 5:28 PM ET
Strategic Storage Trust VI closes $500 million all-stock merger with SSGT III, growing to 37 facilities
- SST VI completed its all-stock merger with SSGT III on Nov 1, 2026; the deal values SSGT III's real estate portfolio at approximately $500 million.
- Added 12 wholly-owned facilities (9,215 units, 981,465 sq ft), bringing the portfolio to 37 facilities, ~30,000 units and 3.2 million sq ft in 10 states and 3 Canadian provinces.
- Created Series G Convertible Preferred Stock paying 8.85% with a $1,000 liquidation preference and $10.75 conversion price; Extra Space Storage LP signed the investors' rights agreement.
INO
INOVIO PHARMACEUTICALS, INC.
regulatory
positive
materiality 0.92
November 2, 2026, 7:15 AM ET
Inovio wins FDA accelerated approval of VOCERYQ, first U.S.-approved DNA medicine, for RRP
- FDA granted accelerated approval for VOCERYQ (formerly INO-3107) to reduce frequency of surgery in adults with recurrent respiratory papillomatosis (RRP).
- Pivotal RRP-001: 7 of 26 efficacy patients (27%, 95% CI 12-48%) had complete response — no surgical excision 12 months after treatment; median 4.5 prior surgeries.
- Inovio expects VOCERYQ to be orderable and shipping in about 60 days, with full field deployment in Q1 2027; Syneos Health engaged for commercial and medical field teams.
regulatory
positive
materiality 0.85
November 2, 2026, 7:15 AM ET
FDA accepts uniQure's Huntington's gene therapy BLA, grants Priority Review with PDUFA date May 1, 2027
- FDA accepted for review the BLA for ifezuntirgene inilparvovec (AMT-130) under the Accelerated Approval pathway with Priority Review; PDUFA target action date May 1, 2027.
- In its acceptance letter, FDA said it is tentatively planning to discuss the application at an Advisory Committee meeting; date and timelines not yet finalized.
- Confirmatory study aligned with FDA: ~200 patients randomized 2:1 to ifezuntirgene inilparvovec vs standard of care, Total Functional Capacity primary endpoint at 36 months.